In this issue: CDMOs use of digital twins to realise a strategic advantage, Physical AI's rise in pharma manufacturing, and more.

Antibody‑drug conjugates (ADCs) remain an area of extreme focus in the pharmaceuticals space, with the market projected to hit a $40bn valuation by 2040. However, technical hurdles in the field remain ...

AI pharmaceutical-development unicorn Deep Intelligent Pharma has recently completed a new financing round of US$60 million. New investors in this round include Trustar Capital, Jinyi Capital, and ...